SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Roger Cranwill who wrote (1388)12/4/1997 1:13:00 AM
From: Howard Hoffman  Read Replies (3) of 1762
 
Any of our more medically-knowledgable posters wish to comment? To this layman, this candidate sounds much improved over CE9.1. The fact that SK (who bailed on CE9.1) is in on this one makes it sound very promising. I especially liked that they announced that they are going directly into Phase II trials now.

Response to approval of Rituxan was a non-event. It should be interesting to see how IDEC develops in terms of earnings now that it is transforming from a 100% R&D company to a real pharmaceutical company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News